Indivior PLC $INDV Stock Purchased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA boosted its position in Indivior PLC (NASDAQ:INDV) by 13.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 328,777 shares of the company’s stock after purchasing an additional 39,319 shares during the period. Pictet Asset Management Holding SA owned about 0.28% of Indivior worth $12,017,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in the business. Two Seas Capital LP increased its position in Indivior by 5.5% during the 3rd quarter. Two Seas Capital LP now owns 3,671,072 shares of the company’s stock worth $131,608,000 after purchasing an additional 191,579 shares during the period. Assenagon Asset Management S.A. grew its holdings in Indivior by 129.8% during the third quarter. Assenagon Asset Management S.A. now owns 3,540,344 shares of the company’s stock worth $126,921,000 after acquiring an additional 1,999,416 shares during the period. Newtyn Management LLC acquired a new position in Indivior during the second quarter worth $53,577,000. Hennion & Walsh Asset Management Inc. purchased a new position in Indivior in the second quarter worth $14,781,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new position in Indivior in the second quarter worth $7,988,000. Hedge funds and other institutional investors own 60.33% of the company’s stock.

Insider Activity

In other Indivior news, CAO Woodrow D. Anderson purchased 1,500 shares of Indivior stock in a transaction on Thursday, August 27th. The shares were bought at an average price of $35.69 per share, with a total value of $53,535.00. Following the completion of the acquisition, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.74% of the stock is owned by company insiders.

Indivior Stock Up 0.2%

NASDAQ:INDV opened at $28.21 on Friday. The company has a market capitalization of $3.33 billion, a PE ratio of 7.88 and a beta of 0.84. Indivior PLC has a 52-week low of $27.68 and a 52-week high of $42.81. The stock has a fifty day simple moving average of $34.37 and a 200-day simple moving average of $35.52.

Indivior (NASDAQ:INDV) last released its quarterly earnings data on Thursday, October 29th. The company reported $1.32 EPS for the quarter, topping the consensus estimate of $1.06 by $0.26. Indivior had a net margin of 32.75% and a negative return on equity of 418.04%. The business had revenue of $356.00 million for the quarter, compared to analyst estimates of $329.35 million. As a group, equities analysts anticipate that Indivior PLC will post 3.66 earnings per share for the current year.

Indivior Dividend Announcement

The firm also recently declared a special dividend, which was paid on Friday, November 6th. Shareholders of record on Friday, October 30th were issued a $8.13 dividend. The ex-dividend date of this dividend was Tuesday, November 3rd.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Barclays raised their target price on Indivior from $43.00 to $45.00 and gave the company an “overweight” rating in a report on Wednesday, October 28th. Wall Street Zen lowered shares of Indivior from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 31st. Zacks Research raised shares of Indivior from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 2nd. Craig Hallum reiterated a “buy” rating and issued a $53.00 price target on shares of Indivior in a report on Tuesday, August 4th. Finally, Weiss Ratings downgraded shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, September 24th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $46.40.

Indivior Company Profile

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment. The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.